You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
29 April 2024
Annual financial statements 2023
30 August 2023
Halbjahresabschluss 2023
Half-yearly financial statements 2023
5 May 2023
Annual financial statements 2022
28 October 2022
Half-yearly financial statements 2022
18 May 2022
Annual financial statements 2021
21 September 2021
Half-yearly financial statements 2021
Halbjahresabschluss 2021
17 May 2021
Annual financial statements 2020
29 September 2020
Halbjahresabschluss 2020
Half-yearly financial statements 2020
25 May 2020
Annual financial statements 2019
24 September 2019
Half-yearly financial statements 2019
Halbjahresabschluss 2019
15 May 2019
Annual financial statements 2018
17 September 2018
Halbjahresabschluss 2018
28 May 2018
Jahresabschluss 2017
6 October 2017
Halbjahresabschluss 2017
24 May 2017
Jahresabschluss 2016
20 September 2016
Half-yearly financial statements 2016
12 June 2016
Jahresabschluss 2015
14 September 2015
Halbjahresabschluss 2015
1 July 2024
Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2)
28 June 2024
FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
13 June 2024
Formycon reports on the results of the Annual General Meeting
Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda
15 May 2024
MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region
8 May 2024
Formycon reports on successful operating business and financial figures for the first quarter of 2024
Aug
2024
Publication half-yearly financial statements
25
Nov 24
Analysts’ Conference
Nov
Press Release – quarterly statement (call-date Q3)